Peptic Ulcer Disease

Clinical Trials of Oral Vaccine Against Peptic Ulcer Disease

Published in Cancer Weekly, February 13th, 1995

OraVax Inc. announced the initiation of a Phase I clinical trial at the Centre Hospital Universitaire Vaudois in Lausanne, Switzerland, of its oral vaccine against Helicobacter pylori.

H. pylori is the bacteria which has been recognized by the U.S. National Institutes of Health, the World Health Organization (WHO) and the worldwide medical community as the principal cause of peptic ulcer disease and gastritis.

The OraVax oral vaccine is designed both as a cure and prevention for H. pylori infection, which in the United States alone affects 20 percent of the population between 20 and 30, and over 50 percent by the age of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry